RAD51 and ovarian carcinoma: Currently, it has been found that RAD51 and PFKP [29, 30], among others, undergo lactylation modification in ovarian cancer, and the lactylation modification of these proteins further enhances their resistance to platinum-based drugs in ovarian cancer.